Voyager Therapeutics Inc
NASDAQ:VYGR
Intrinsic Value
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. [ Read More ]
The intrinsic value of one
VYGR
stock under the Base Case scenario is
3.63
USD.
Compared to the current market price of 7.65 USD,
Voyager Therapeutics Inc
is
Overvalued by 52%.
Voyager Therapeutics Inc's market capitalization is 415.4m USD.
VYGR stock price is 7.65 USD.
VYGR stock (3.63 USD) is 52% less than its price (7.65 USD).
VYGR. Open DCF Valuation
VYGR stock (3.63 USD) is 52% less than its price (7.65 USD). Open Relative Valuation
VYGR has upside potential of 137% compared to the average analyst price target.
Open Wall St Estimates
VYGR has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
VYGR's Revenue has been growing by 13% per year for the last 3 years.
VYGR's Revenue has grown by an exceptional 511% over the past 12 months.
VYGR's ROE (Return on Equity) has significantly increased in the last 3 years from 36% to 90%.
VYGR's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from 37% to 154%.
VYGR has a very low three-year average ROE (Return on Equity): 1%. The company is not efficient at transforming stockholders' equity into net income.
VYGR has positive Operating Income for the last twelve months.
VYGR has positive Net Income for the last twelve months.
VYGR's ROE (Return on Equity) for the past 12 months is very high and is equal to 90%.
VYGR's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 154%.
VYGR's Altman Z-Score is very high and is equal to 3.29.
VYGR's Revenue is forecast to fall at a rate of 39% per year over the next 3 years.
VYGR's long-term assets (351m USD) exceed its long-term liabilties (115m USD).
VYGR has positive Free Cash Flow for the last twelve months.
VYGR's short-term assets (320m USD) exceed its short-term liabilties (65m USD).
VYGR's D/E (Debt to Equity) is very low and is equal to 0.
Valuation Backtest
Voyager Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
VYGR
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Voyager Therapeutics Inc
Balance Sheet Decomposition
Voyager Therapeutics Inc
| Current Assets | 319.7m |
| Cash & Short-Term Investments | 230.9m |
| Receivables | 83.5m |
| Other Current Assets | 5.3m |
| Non-Current Assets | 31.6m |
| PP&E | 30m |
| Other Non-Current Assets | 1.6m |
| Current Liabilities | 64.5m |
| Accounts Payable | 1.6m |
| Accrued Liabilities | 20m |
| Other Current Liabilities | 42.9m |
| Non-Current Liabilities | 50.5m |
| Other Non-Current Liabilities | 50.5m |
Earnings Waterfall
Voyager Therapeutics Inc
|
Revenue
|
250m
USD
|
|
Operating Expenses
|
-128m
USD
|
|
Operating Income
|
122m
USD
|
|
Other Expenses
|
10.3m
USD
|
|
Net Income
|
132.3m
USD
|
Free Cash Flow Analysis
Voyager Therapeutics Inc
What is Free Cash Flow?
VYGR Profitability Score
Profitability Due Diligence
Voyager Therapeutics Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Voyager Therapeutics Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
VYGR Solvency Score
Solvency Due Diligence
Voyager Therapeutics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Voyager Therapeutics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VYGR Price Targets Summary
Voyager Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
VYGR
is 18.13 USD
with a low forecast of 10.1 USD and a high forecast of 31.5 USD.
Ownership
VYGR Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
VYGR Price
Voyager Therapeutics Inc
| Average Annual Return | -9.85% |
| Standard Deviation of Annual Returns | 74.74% |
| Max Drawdown | -91% |
| Market Capitalization | 415.4m USD |
| Shares Outstanding | 54 300 600 |
| Percentage of Shares Shorted | 7.33% |
VYGR News
Last Important Events
Voyager Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Voyager Therapeutics Inc
Company Profile
Voyager Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.
Contact
IPO
Employees
Officers
The intrinsic value of one
VYGR
stock under the Base Case scenario is
3.63
USD.
Compared to the current market price of 7.65 USD,
Voyager Therapeutics Inc
is
Overvalued by 52%.
You don't have any saved screeners yet
